ASBP Market Analysis
News & Sentiment
49 articles · sorted by datePage 1 of 3 · 49 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-7.090.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$8.4MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.18
- P/S (TTM)
- 244.39
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -5759.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 0.15
Last earnings
May 15, 2026 · Reported $-20.57
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Aspire BioPharma, Inc.
Company profileAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 23150 FASHION DRIVE, ESTERO, FL
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$8.4M
Shares outstanding$1.3M
52W high$1,050.36
52W low$3.31
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent